Coinbase
COIN
Tesla
TSLA
Salesforce
CRM
4
Amazon
AMZN
5
Meta Platforms
META
US Stock MarketDetailed Quotes
BCYC Bicycle Therapeutics
- 9.660
- -0.130-1.33%
Trading Mar 11 11:04 ET
668.49MMarket Cap-3.33P/E (TTM)
10.225High9.600Low52.65KVolume9.780Open9.790Pre Close513.33KTurnover0.12%Turnover RatioLossP/E (Static)69.20MShares28.67052wk High0.84P/B425.46MFloat Cap9.58052wk Low--Dividend TTM44.04MShs Float62.075Historical High--Div YieldTTM6.38%Amplitude6.240Historical Low9.749Avg Price1Lot Size
About Bicycle Therapeutics Company
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Company Profile
SymbolBCYC
Company NameBicycle Therapeutics
Listing DateMay 23, 2019
Issue Price14.00
Founded2009
CEODr. Kevin Lee, M.B.A.
MarketNASDAQ
Employees305
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressGranta Park Great Abington,Portway Building,Blocks A & B
CityCambridge
ProvinceCambridgeshire
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeCB21 6GS
Phone44-1223-261503
Company Executives
- Name
- Position
- Salary
- Dr. Kevin Lee, M.B.A.
- Director and Chief Executive Officer
- 5.54M
- Dr. Nicholas Keen, PhD
- Chief Scientific Officer
- --
- Dr. Santiago Arroyo
- Chief Development Officer
- 2.68M
- Travis Thompson
- Chief Accounting Officer
- --
- Alethia Young
- Chief Financial Officer
- 2.88M
- Dr. Michael Skynner, PhD
- Chief Technology Officer
- --
- Nigel Crockett
- Chief Business Officer
- --
- Dr. Michael Charles Ferguson Hannay, D.Sc.
- Chief Product and Supply Chain Officer
- --
- Alistair Milnes
- Chief Operating Officer
- --
- Pierre Legault, C.P.A.,M.B.A.
- Chairman of the Board
- 1.06M
- Dr. Felix J. Baker,PhD
- Independent Director
- --
- Sir Greg Winter, F.R.S.
- Independent Director
- 477.04K
- Dr. Jose-Carlos Gutierrez-Ramos, PhD
- Independent Director
- 482.29K
- Janice Bourque, M.B.A.
- Independent Director
- 495.41K
- Stephen Sands
- Independent Director
- --
- Richard N. Kender, M.B.A.
- Independent Director
- 526.91K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!